FIG 1.

RNA sequencing performance evaluation design and flow of participants. In total, 261 participants were included in the prospective cohort, after excluding samples for which no malignancy was present and RNA failed to be isolated; a total of 244 individuals had samples analyzed in parallel for gene fusions using RNA sequencing and traditional diagnostic methods. ^aOn the basis of sample isolation during the period of the RNA-seq performance evaluation, we estimate that 2.7% of samples were excluded because of insufficient RNA.